Where is Viatris Inc. (VTRS) Headed According to the Street?

Core Insights - Viatris Inc. (NASDAQ:VTRS) is recognized as a promising healthcare stock priced under $50, with a recent price target adjustment from Piper Sandler to $12 from $9 while maintaining a Neutral rating, indicating confidence in the brand's performance across various geographies and potential steady contributions from new product launches [1] Product Launch and Strategy - On January 20, Viatris announced the launch of Inpefa® (sotagliflozin) in the UAE, marking it as the first country within its territories to commercialize this treatment, with plans for future launches in several countries to enhance treatment access in key markets outside Europe and the U.S. [2] - Inpefa is the first and only dual SGLT1/2 inhibitor approved for treating heart failure, with approvals in the UAE and the U.S. to reduce hospitalization risks for heart failure and cardiovascular-related issues in adults with heart failure or type 2 diabetes, chronic kidney disease, and other cardiovascular risk factors [3] Company Overview - Viatris is a global healthcare company offering a wide range of healthcare and pharmaceutical products across various therapeutic areas, including oncology, cardiovascular, dermatology, immunology, eye care, gastroenterology, and women's healthcare. Its operations are segmented into Developed Markets, Greater China, JANZ, and Emerging Markets [4]